A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
NCT ID: NCT00048139
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
52 participants
INTERVENTIONAL
2001-10-31
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Irinotecan
250mg/m2 iv on day 1 of each 3 week cycle
capecitabine [Xeloda]
1000mg/m2 po bid on days 1-15 of each 3 week cycle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Irinotecan
250mg/m2 iv on day 1 of each 3 week cycle
capecitabine [Xeloda]
1000mg/m2 po bid on days 1-15 of each 3 week cycle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* locally advanced and/or metastatic colorectal cancer;
* \>=1 target lesion.
Exclusion Criteria
* previous systemic therapy for metastatic disease;
* progressive disease during previous adjuvant therapy or within 6 months of completion.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix, Arizona, United States
Fountain Valley, California, United States
La Jolla, California, United States
Santa Rosa, California, United States
Denver, Colorado, United States
Hutchinson, Kansas, United States
Las Vegas, Nevada, United States
Albuquerque, New Mexico, United States
Albuquerque, New Mexico, United States
Buffalo, New York, United States
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MO16461
Identifier Type: -
Identifier Source: org_study_id